You just read:

Elusys Therapeutics Announces Publication Of Results From Five Clinical Trials With Its Inhalational Anthrax Antitoxin, ANTHIM® (obiltoxaximab) Injection

News provided by

Elusys Therapeutics, Inc.

Sep 14, 2016, 10:00 ET